Delivery Order SPE2DB22D1106-SPE2DB24FFGB3
Award Date
8/12/24
Potential Completion Date
9/3/24
Potential Value
$58K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $57,795.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is a Delivery Order for the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML, with a completion date of June 4, 2024. Amerisourcebergen Drug Corp's Corporate Office Division is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $73,824.95 firm-fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialized pharmaceutical product. The contract has an ultimate completion date of September 24, 2024. This award is likely part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract, valued at up to $115,590.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract, valued at $46,236.16, is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The order has an ultimate completion date of August 14, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded several federal contracts and indefinite delivery contracts (IDCs) by various defense and...
This federal contract award to Amerisourcebergen Drug Corporation's Corporate Office Division is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The contract, valued at $11,559.04, was awarded on October 15, 2024 by the Defense Logistics Agency (DLA) Troop Support Medical, a major customer of Amerisourcebergen. The contract has a firm fixed price and an ultimate completion date of November 5, 2024. This award is part of a larger Indefinite Delivery Contract (IDC)...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract, valued at $92,472.32, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a U.S. government agency. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025,...
This federal contract award, issued by the Defense Logistics Agency (DLA), was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,038.58, is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of March 24, 2025 and is a firm fixed-price contract. The contract is not designated with a set-aside requirement, indicating open...
This is a delivery order awarded to AmerisourceBergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA). The $231,180.80 firm fixed-price contract is for the supply of 4,565,214,858 units of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract has an ultimate completion date of August 9, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract, valued at $69,354.24, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product. This is a delivery order contract with a firm fixed price pricing type, and the ultimate completion date is July 15, 2024. AmerisourceBergen Drug Corp is a major supplier of pharmaceutical products and medical supplies to the U.S. federal...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $120,192.80, is a delivery order for the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML. It is a firm fixed price contract with a period of performance through July 1, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...